A recent safety review of breast implant-associated anaplastic large cell lymphoma, also known as BIA-ALCL, by Health Canada found that the rate of cases reported to the Department is relatively low.
BIA-ALCL is a rare type of non-Hodgkin lymphoma which affects the immune system, that may develop many months or years following a breast implant procedure. The disease is, however, not a cancer of the breast tissue.
BIA-ALCL usually presents as an accumulation of fluid, known as serum fluid, between the implant and the surrounding tissue. Although the cause of BIA-ALCL, which occurs with both saline-filled and silicone gel-filled breast implants, is unknown, it is a highly treatable type of lymphoma.
According to the most recent data available published by the American Society of Plastic Surgeons, shows that in the United States women have a lifetime risk of association between breast implants and ALCL of 1 in 30,000 patients with textured implants. Some other countries have reported risks between 1 in 1,000 to one in 30,000 people.
Since the initial case report in 1996, there are 183 cases of BIA-ALCL reported in the United States an a total of 439 worldwide.
Health Canada undertook the safety review because of an increase in reporting of BIA-ALCL internationally.
In the last 1o years, 5 confirmed Canadian cases of BIA-ALCL have been reported by Canadian manufacturers. This is equal to 1 case of BIA-ALCL per 77,190 implants sold, or 0.0013%. However, Health Canada acknowledges that some cases may not have been reported to the manufacturers or Health Canada during this time period.
Textured Surface Implants
Available data suggest that BIA-ALCL is more frequently reported with textured surface (beast) implants than smooth surface implants. Textured surface implants account for a quarter of all breast implants sold in Canada. Four of the five reported Canadian cases of BIA-ALCL involved textured surface implants. The surface type was not reported in the remaining case. The rate of occurrence of BIA?ALCL per textured implant sold in Canada is 1 case per 24,177 or 0.0041%.
As a result of its safety review, Health Canada is working with manufacturers to update the safety information on the product labelling for all breast implants. Health Canada is also communicating this important safety information to Canadians through the Recalls and Safety Alerts database on the Healthy Canadians website.
Health Canada continues to monitor the safety profile of breast implants through its post-market surveillance program, to help ensure that the benefits of these products continue to outweigh the risks. Health Canada will also monitor cases of BIA-ALCL through an annual follow-up with manufacturers of breast implants.
|Information for healthcare professionals||Learn more about the signs, symptoms and testing steps to recognize and diagnose BIA?ALCL.|
|Report incidents of BIA-ALCL to Health Canada.||Include specific details, such as symptoms, how BIA-ALCL was discovered, age of patient at implantation, prior implant history, age of patient at discovery, tests conducted to diagnose, staging information, course of therapy and clinical outcomes.|
|Health Canada||Call toll-free at 1-866-234-2345.|
|Review Information on Health Canada’s webpage on Adverse Reaction Reporting for information on how to report online, by mail or by fax.|
|What consumers should do|
|If you have breast implants|
|If you are considering a breast implant|
Last Editorial Review: November 24, 2017
Featured Image: Cancer Patient.?Courtesy: ? Fotolia | Used with permission.
Copyright ? 2017 Sunvalley Communication, LLC. All rights reserved. Republication or redistribution of Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of Sunvalley Communication. Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco?Zine, Oncozine and The Onco?Zine Brief are registered trademarks and trademarks of Sunvalley Communication around the world.